Reported figures and Equlion model projections for the next 5 years.
Metric
2025 (actual)
2026 (forecast)
2027
2028
2029
2030
2031
Trend
ROE
-82.39%
-108.77%
-192.6%
207.13%
74.34%
45.91%
33.21%
ROA
-47.86%
-63.72%
-81.97%
-132.45%
-148.02%
-156.67%
-163.06%
Gross Margin
19.87%
17.28%
17.28%
17.28%
17.28%
17.28%
17.28%
Sector average
-
17.71%
17.71%
17.71%
17.71%
17.71%
Amounts in SEK (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.
Want the full financial forecast report for Egetis Therapeutics AB (publ)? It covers the balance sheet, income statement and Equlion model projections.
62.35%
Net Margin
-548.88%
-609.51%
-594.12%
-596.42%
-597.07%
-597.44%
-597.61%
Total Assets
SEK 639,100.00K
SEK 760,500.00K
SEK 391,698.28K
SEK 404,599.07K
SEK 423,976.79K
SEK 436,586.14K
SEK 445,421.95K
Sector average
-
SEK 2,900,240.60K
SEK 3,045,009.79K
SEK 3,280,286.42K
SEK 3,536,407.14K
SEK 3,762,908.71K
SEK 1,806,991.80K
Net Income
-SEK 342,500.00K
-SEK 445,920.00K
-SEK 472,226.77K
-SEK 527,331.87K
-SEK 613,216.98K
-SEK 674,140.09K
-SEK 719,101.94K
Sector average
-
-SEK 22,027.28K
-SEK 904.69K
-SEK 7,253.84K
-SEK 3,858.45K
-SEK 1,547.00K
-SEK 13,704.11K
Valuation
-
SEK 2,482,916.10K
SEK 2,629,394.20K
SEK 2,936,223.53K
SEK 3,414,438.29K
SEK 3,753,662.70K
SEK 4,004,013.69K
Sector average
-
SEK 5,151,301.60K
SEK 5,189,236.02K
SEK 5,317,343.69K
SEK 5,514,329.75K
SEK 5,636,782.17K
SEK 3,179,755.44K
Stock Price
-
SEK 5.34
SEK 5.66
SEK 6.31
SEK 7.34
SEK 8.07
SEK 8.61
Sector average
-
SEK 48.04
SEK 48.69
SEK 50.45
SEK 52.13
SEK 53.41
SEK 36.70
Egetis Therapeutics AB (publ) (EGTX.ST) Financial Forecast | Equlion
